Thursday, June 27, 2024
Skyhawk Therapeutics, Inc., a clinical-stage biotech company focused on developing innovative small molecule therapies that target critical RNA molecules, has announced its expansion into new state-of-the-art laboratories at Superlab Suisse in Basel, Switzerland.
Skyhawk Therapeutics, stated, "We have achieved significant scientific advancements at our Basel location. This new space will enable us to grow our talented senior scientific team and enhance our capabilities in developing therapies for some of the world's most challenging diseases."
Skyhawk Therapeutics, added, "This is a pivotal moment for Skyhawk. Our first program for Huntington's disease is progressing in the clinic, and our second program, SKY-1214, is on track to enter clinical trials. We've doubled our lab space in Basel to support a series of promising INDs. Superlab Suisse offers cutting-edge research facilities and dynamic infrastructure for Switzerland's life sciences sector. We are excited to be part of this thriving biotechnology hub in Basel."
Skyhawk's platform integrates four distinct data sets within advanced machine learning models to accelerate the development of RNA-targeting small molecule drug candidates across a range of targets.
Source: prnewswire.com
